GB2038629A - Dietary compositions - Google Patents
Dietary compositions Download PDFInfo
- Publication number
- GB2038629A GB2038629A GB7939669A GB7939669A GB2038629A GB 2038629 A GB2038629 A GB 2038629A GB 7939669 A GB7939669 A GB 7939669A GB 7939669 A GB7939669 A GB 7939669A GB 2038629 A GB2038629 A GB 2038629A
- Authority
- GB
- United Kingdom
- Prior art keywords
- product
- amino acids
- category
- capsules
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
Abstract
Dietary compositions wherein necessary amino acids are provided as two components, one incorporating the more palatable amino acids, and the other comprising the more unpalatable amino acids in an amount of no than about 20% by weight of the total, the taste of the second component being disguised, masked or otherwise rendered easily taken through the mouth, e.g. by coating, tableting or encapsulation, so that both components may readily be assimilated at substantially the same time.
Description
SPECIFICATION
Dietary compositions
This invention relates to compositions for human use in treating diseases of the kind susceptible to dietetic management, such diseases being mostly, but not all, classified as "inborn errors of metabolism".
An inborn error of metabolism usually is caused by an inherited deficiency of one or more of the enzymes concerned with metabolism. This often leads to an accumulation of metabolites. Such an accumulation can lead to direct and/or indirect adverse effects due to the production of abnormal amounts of metabolites. This is well illustrated by, for example, Phenylketronuria (PKU). This latter is an inborn error of amino acid metabolism discovered by Folling (J. Physiol Chem. 227,69, 1934). This disease is associated with severe mental retardation, and in its classical form consists of a deficiency of the enzyme Phenylalanine Hydroxylase.When protein is eaten by a person suffering from PKU and is hydrolysed into its constituent amino acids, one of the amino acids, phenylalanine is not metabolized properly due to the enzyme deficiency and accumulates in the blood and body fluids thus:-
It is this result of accumulation of phenylalanine and its abnormal metabolites which causes mental retardation and other physical and personality defects.
Bickel, Gerrard and Hickmans (lancet 2, 812, 1953) treated PKU by means of a diet that was very low in phenylalanine and found that plasma phenylalanine levels could be controlled. Such a diet must of course contain all the nutrients for normal growth and development. Later it was found that if such a treatment was started very shortly after birth an affected child would grow up normally providing that the dietary phenylalanine levels were kept within certain limits.
Up to the present time the only way to control the phenylalanine level is by controlling its intake, that is by means of a special diet. Unfortunately the diet is very unpleasant due mainly to the fact that all known proteins have a level of phenylalanine too high for use in such a diet and therefore the level has to be artificially lowered by either a) hydrolysing the protein into its amino acids and removing the phenylalanine, or b) making up the diet using pure crystalline amino acids omitting phenylalanine. In both cases the resultant product has a taste which to most persons is highly objectionable.
The objectionable taste of such products, with
which the invention is more particularly, but not
exclusively, concerned is due to the tastes of amino
acids some of which are pleasant being sweettast- ing, some bitter, and so on, and which together con
stitute a diet that is almost unbearable to take. As
children involved perforce have to rely on this very
unpleasant diet for the major part of their "protein"
intake, there has been a continuous search by the
manufacturers of such dietary compositions for
methods of improving their acceptability.
The object of the present invention therefore is to
provide a novel dietary product regime that is par
ticularly suitable for treating inborn errors of
metabolism, and is less objectionable, even pleas
ant, to the taste, and thus more acceptable than
heretofore.
Broadly, the invention, is predicated upon a pro
duct regime wherein necessary acids are provided
as two components, one incorporating the more
palatable amino acids, and the other comprising the
more unpalatable amino acids in an amount of no
more than about 20% by weight of the total, the taste
of the said second component being disguised,
masked or otherwise rendered easily taken through
the mouth, e.g. by coating, tableting or encapsula
tion, so that both components may readily be assimi
lated at substantially the same time.
Individual aspects of the invention comprise such
a dietary regime or method of treatment and, sepa
rately, its two components.
A further aspect of the invention involves asses
sing the tastes of all the individual amino acids of
what is known to constitute a satisfactory dietary
product, classifying them into two groups, i.e.
"compatible or pleasant" and "incompatible or
unpleasant", altering the composition of the product
to increase the amount in the first category and
decrease the amount in the second category whilst
retaining at least a minimum dietetic quality so that the second category of amino acids (unpleasant or
incompatible) is reduced in proportion substantially
to or below 20% by weight of the total, and preparing
said second category, e.g. in tableted, encapsulated,
coated, or the like form, to disguise or mask its
unpleasant taste.
Thus prepared, the compatible group of amino
acids can be used with much greater flexibility than
the total mixture as previously provided, being
usable with almost any kind offlavouring. The i incompatible amino acids in the form of tablets, cap
sules etc, is readily acceptable, the only proviso
being that it is essential that the two components of
the diet are assimilated at about the same time.
In a preferred embodiment of the invention, the
more unpalatable amino acids are separated from
the more palatable amino acids and formed into fine
capsules, for example of 1 mm diameter, these cap
sules then being added to the more palatable amino
acids in powder form. The capsules and powder are
formed into a substantially homogeneous mixture,
for example, by means of a rotating plough mixer.
The powder will to some extent adhere to the cap
sules in a very fine layer. The resultant mixture
allows for simultaneous assimilation of the more
palatable and the more unpalatable amino acids with reasonable masking of the objectionable taste of the more unpalatable amino acids.
The invention is applicable to all diets involving amino acids, including other inborn errors in metabolism such for example as Maple Syrup Urine
Disease, Tyrosinemia, and Homocystinuria. Other applications include the dietary treatment of Cystic
Fibrosis and the-provision of the amino acids constituents of "Elemental" or "Defined" diets as used for many conditions.
This invention will now be further described by means of the following example.
Example
A typical example of a conventional dietary product for PKU children is as follows:- -B
Amino Acid
L ALANINE LARGININE L ARSPARTIC ACID
L CYSTINE
L GLUTAMIC ACID
GLYCINE L HISTIDINE L ISO LEUCINE
L LEUCINE
L LYSINE
L METHONINE L PHENYLALANINE L PROLINE L SERINE
L THREONINE
L TRYPTOPHAN L TYROSINE
L VALINE
Total
A PKU child would need about 29 per kg of weight per day of such a product combination. For example a four year old child weighing say 17 kg would
require about 359 total of which 31.79 would be of the bland (i.e. compatible or pleasant tasting) mixture which could be taken in a number of ways, and 3.39 of the incompatible (bad tasting) mixture in the form of tablets, capsules or the like. In the form of tablets, say about the size of ordinary aspirin tablets,
1 to 2, three times a day with meals, would suffice.
Claims (13)
1.5g 6g 49
49 ~
90.59 9.5g the more palatable amino acids, and the other comprising the more unpalatable amino acids in an amount of no more than about 20% by weight of the total, the taste of said second component being disguised or masked or otherwise rendered easily taken through the mouth.
2. A product as claimed in claim 1 wherein the second component is masked by coating tableting or encapsulation.
3. A product as claimed in claim 2 wherein the first component is in the form of a powder and the second component is in the form of capsules.
4. A product as claimed in claim 3 wherein the capsules have a diameter of about Imam.
5. A product as claimed in claim 3 or 4 which is in the form of a substantially homogeneous mixture.
6. A product as claimed in claim 1 and substantially as hereinbefore described with reference to the
Example.
7. A method of preparing a product as claimed in claim 1 comprising assessing the tastes of the necessary individual amino acids for a satisfactory dietary product, classifying them into two categories, i.e. more palatable and more unpalatable, altering the composition of the product to increase the amount in the first category and decrease the amount in the second category whilst retaining at least a minimum dietetic quality so that the second category of amino acids is reduced-in proportion to or below about 20% by weight of the total, and preparing said second category tb disguise or mask its unpleasant taste.
8. A method as claimed in claim 7 wherein the second category is masked or disguised by coating, tableting or encapsulation.
9. A method as claimed in claim 7 or8 wherein said first category is formed as a powder and said second category is formed as capsules.
10. A method as claimed in claim 9 wherein the capsules have a diameter of about 1 mm.
11. A method as claimed in any one of claims 7 to 10 including the step offorming said first and second categories into a substantially homogeneous mixture.
12. A method as claimed in claim 11 wherein the substantially homogeneous mixture is formed by means of a rotating plough mixer.
13. A method as claimed in claim 7 and substantially as hereinbefore described with reference to the
Example.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7939669A GB2038629A (en) | 1978-11-17 | 1979-11-16 | Dietary compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7844931 | 1978-11-17 | ||
GB7939669A GB2038629A (en) | 1978-11-17 | 1979-11-16 | Dietary compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
GB2038629A true GB2038629A (en) | 1980-07-30 |
Family
ID=26269619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB7939669A Withdrawn GB2038629A (en) | 1978-11-17 | 1979-11-16 | Dietary compositions |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2038629A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
US5550146A (en) * | 1992-12-23 | 1996-08-27 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
WO2001097635A2 (en) * | 2000-06-20 | 2001-12-27 | Coraltis Ltd. | Microcapsules containing arginine and the different uses thereof |
EP1774858A1 (en) * | 2005-10-13 | 2007-04-18 | Valpharma International S.P.A. | Nutritional compositions based on amino acids |
-
1979
- 1979-11-16 GB GB7939669A patent/GB2038629A/en not_active Withdrawn
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
US5550146A (en) * | 1992-12-23 | 1996-08-27 | Abbott Laboratories | Medical foods for the nutritional support of infant/toddler metabolic diseases |
US5587399A (en) * | 1992-12-23 | 1996-12-24 | Abbott Laboratories | Method for preparing medical foods for the nutritional support of infants/toddlers with metabolic diseases |
WO2001097635A2 (en) * | 2000-06-20 | 2001-12-27 | Coraltis Ltd. | Microcapsules containing arginine and the different uses thereof |
WO2001097635A3 (en) * | 2000-06-20 | 2002-04-11 | Coraltis Ltd | Microcapsules containing arginine and the different uses thereof |
EP1774858A1 (en) * | 2005-10-13 | 2007-04-18 | Valpharma International S.P.A. | Nutritional compositions based on amino acids |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4921877A (en) | Liquid nutritional formula for glucose intolerance | |
EP0923315B1 (en) | Nutritional formula for phenylketonuria patients | |
CA1140855A (en) | Composition and method for suppressing appetite for calories as carbohydrates | |
JP2599400B2 (en) | Formulated liquid nutritional composition for glucose intolerant patients | |
CA2371696A1 (en) | Composition for an infant formula having a low threonine content | |
US6605646B2 (en) | Vitamin supplement composition | |
FR2657013A1 (en) | DIETETIC COMPOSITION BASED ON POLYPEPTIDES AND AMINO ACIDS. | |
Rose | The role of the amino acids in human nutrition | |
GB2038629A (en) | Dietary compositions | |
Peng et al. | Effects of amino acid imbalance and protein content of diets on food intake and preference of young, adult, and diabetic rats | |
EP0461261A1 (en) | Oligopeptide mixture and composition containing the same | |
Pennisi et al. | Effects of protein and amino acid diets in chronically uremic and control rats | |
Zambotti et al. | Selective effect of a maize diet in reducing serum and brain tryptophan contents and blood and brain serotonin levels | |
US20010011070A1 (en) | Use of threonine for the treatment of phenylketonuria | |
JPH11269078A (en) | Calcium absorption promoter and calcium-replenishing food and drink | |
JPH07215851A (en) | Antiallergic agent and its production | |
JPH04126051A (en) | Nutritional preparation for patient suffering from phenylketonuria | |
Reeves et al. | The effect of dietary tyrosine levels on food intake in zinc-deficient rats | |
Paz et al. | Malnutrition induces an increase in intermediate filament protein content of rat cerebral cortex | |
US4211768A (en) | Dietetic foodstuff and its production | |
RU2161888C1 (en) | Sweets | |
JPH06247876A (en) | Medicine for improving alcoholic hepatopathy | |
JPH02227049A (en) | Healthy food suppressing rise in cholesterol in blood | |
Ghazal et al. | Effect of oral contraceptives (Lyndiol®) on rat brain gamma aminobutyric acid system | |
Blažek et al. | The Effect of α-Tocopherol Acetate on Plasma Esterified Cholesterol in Patients with Chronic Liver Disease/Einfluß des α-Tokopherolazetats auf Plasmacholesterolester bei Kranken mit chronischen Leberstörungen/L'action de l'acétate d'α-tocophérol sur la fraction estérifiée du cholésterol plasmatique chez les malades souffrant d'affections hépatiques chroniques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |